Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2018 Oct 22. pii: S0090-8258(18)31303-9. doi: 10.1016/j.ygyno.2018.10.022. [Epub ahead of print] No abstract available.

2.

Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2018 Oct;151(1):18-23. doi: 10.1016/j.ygyno.2018.07.021. Epub 2018 Aug 19. Erratum in: Gynecol Oncol. 2018 Oct 22;:.

PMID:
30135020
3.

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.

Bookman MA, Okamoto A, Stuart G, Yanaihara N, Aoki D, Bacon M, Fujiwara K, González-Martín A, Harter P, Kim JW, Ledermann J, Pujade-Lauraine E, Quinn M, Ochiai K; 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii30-viii35. doi: 10.1093/annonc/mdx449. Review.

4.

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.

Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, Richard SD, Rodriguez N, Birrer MJ, Backes FJ, Geller MA, Quinn M, Goodheart MJ, Mutch DG, Kavanagh JJ, Maxwell GL, Bookman MA.

Gynecol Oncol. 2018 Feb;148(2):275-280. doi: 10.1016/j.ygyno.2017.11.018. Epub 2017 Nov 28.

5.

Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.

Horowitz NS, Larry Maxwell G, Miller A, Hamilton CA, Rungruang B, Rodriguez N, Richard SD, Krivak TC, Fowler JM, Mutch DG, Van Le L, Lee RB, Argenta P, Bender D, Tewari KS, Gershenson D, Java JJ, Bookman MA.

Gynecol Oncol. 2018 Jan;148(1):49-55. doi: 10.1016/j.ygyno.2017.10.011. Epub 2017 Nov 23.

6.

The ISB Cancer Genomics Cloud: A Flexible Cloud-Based Platform for Cancer Genomics Research.

Reynolds SM, Miller M, Lee P, Leinonen K, Paquette SM, Rodebaugh Z, Hahn A, Gibbs DL, Slagel J, Longabaugh WJ, Dhankani V, Reyes M, Pihl T, Backus M, Bookman M, Deflaux N, Bingham J, Pot D, Shmulevich I.

Cancer Res. 2017 Nov 1;77(21):e7-e10. doi: 10.1158/0008-5472.CAN-17-0617.

7.

Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ; Ovarian Cancer Association Consortium, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ.

Gynecol Oncol. 2017 Nov;147(2):396-401. doi: 10.1016/j.ygyno.2017.08.024. Epub 2017 Sep 19.

8.

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH.

Gynecol Oncol. 2017 Nov;147(2):243-249. doi: 10.1016/j.ygyno.2017.08.004. Epub 2017 Aug 12.

9.

To promote maintenance or treatment, is that the question?

Bookman MA, Kitchener HC.

Lancet Oncol. 2017 Sep;18(9):1151-1152. doi: 10.1016/S1470-2045(17)30567-3. Epub 2017 Jul 25. No abstract available.

PMID:
28754484
10.

In Accordance With Our Best Estimates.

Bookman MA.

J Clin Oncol. 2017 Aug 20;35(24):2737-2739. doi: 10.1200/JCO.2017.73.8997. Epub 2017 Jul 12. No abstract available.

PMID:
28700278
11.

Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.

Jang JYA, Yanaihara N, Pujade-Lauraine E, Mikami Y, Oda K, Bookman M, Ledermann J, Shimada M, Kiyokawa T, Kim BG, Matsumura N, Kaku T, Kuroda T, Nagayoshi Y, Kawabata A, Iida Y, Kim JW, Quinn M, Okamoto A.

J Gynecol Oncol. 2017 Jul;28(4):e54. doi: 10.3802/jgo.2017.28.e54. Review.

12.

Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.

Bookman MA, Tyczynski JE, Espirito JL, Wilson TW, Fernandes AW.

Gynecol Oncol. 2017 Jul;146(1):58-63. doi: 10.1016/j.ygyno.2017.04.011. Epub 2017 Apr 26.

PMID:
28454659
13.

Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder.

C Yuen RK, Merico D, Bookman M, L Howe J, Thiruvahindrapuram B, Patel RV, Whitney J, Deflaux N, Bingham J, Wang Z, Pellecchia G, Buchanan JA, Walker S, Marshall CR, Uddin M, Zarrei M, Deneault E, D'Abate L, Chan AJ, Koyanagi S, Paton T, Pereira SL, Hoang N, Engchuan W, Higginbotham EJ, Ho K, Lamoureux S, Li W, MacDonald JR, Nalpathamkalam T, Sung WW, Tsoi FJ, Wei J, Xu L, Tasse AM, Kirby E, Van Etten W, Twigger S, Roberts W, Drmic I, Jilderda S, Modi BM, Kellam B, Szego M, Cytrynbaum C, Weksberg R, Zwaigenbaum L, Woodbury-Smith M, Brian J, Senman L, Iaboni A, Doyle-Thomas K, Thompson A, Chrysler C, Leef J, Savion-Lemieux T, Smith IM, Liu X, Nicolson R, Seifer V, Fedele A, Cook EH, Dager S, Estes A, Gallagher L, Malow BA, Parr JR, Spence SJ, Vorstman J, Frey BJ, Robinson JT, Strug LJ, Fernandez BA, Elsabbagh M, Carter MT, Hallmayer J, Knoppers BM, Anagnostou E, Szatmari P, Ring RH, Glazer D, Pletcher MT, Scherer SW.

Nat Neurosci. 2017 Apr;20(4):602-611. doi: 10.1038/nn.4524. Epub 2017 Mar 6.

14.

CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study.

Ng CS, Zhang Z, Lee SI, Marques HS, Burgers K, Su F, Bauza J, Mannel RS, Walker JL, Huh WK, Rubin SC, DiSilvestro P, Martin LP, Chan JK, Bookman MA, Coleman RL, Lee TY.

Clin Cancer Res. 2017 Jul 15;23(14):3684-3691. doi: 10.1158/1078-0432.CCR-16-1859. Epub 2017 Feb 7.

15.

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.

McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010.

PMID:
28119296
16.

What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD.

Cancer. 2017 May 15;123(6):985-993. doi: 10.1002/cncr.30414. Epub 2016 Nov 16.

17.

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI.

Gynecol Oncol. 2016 Oct;143(1):3-15. doi: 10.1016/j.ygyno.2016.05.022. Epub 2016 Aug 8.

18.

Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.

Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA.

J Clin Oncol. 2016 Nov 10;34(32):3854-3863. doi: 10.1200/JCO.2016.68.1239.

19.

Genome-wide characteristics of de novo mutations in autism.

Yuen RK, Merico D, Cao H, Pellecchia G, Alipanahi B, Thiruvahindrapuram B, Tong X, Sun Y, Cao D, Zhang T, Wu X, Jin X, Zhou Z, Liu X, Nalpathamkalam T, Walker S, Howe JL, Wang Z, MacDonald JR, Chan A, D'Abate L, Deneault E, Siu MT, Tammimies K, Uddin M, Zarrei M, Wang M, Li Y, Wang J, Wang J, Yang H, Bookman M, Bingham J, Gross SS, Loy D, Pletcher M, Marshall CR, Anagnostou E, Zwaigenbaum L, Weksberg R, Fernandez BA, Roberts W, Szatmari P, Glazer D, Frey BJ, Ring RH, Xu X, Scherer SW.

NPJ Genom Med. 2016 Aug 3;1:160271-1602710.

20.

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI.

J Clin Oncol. 2016 Oct 1;34(28):3460-73. doi: 10.1200/JCO.2016.68.6907. Epub 2016 Aug 8.

21.

Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.

Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun C, O'Malley DM, Wright AA.

JAMA Oncol. 2016 Nov 1;2(11):1427-1433. doi: 10.1001/jamaoncol.2016.1842.

22.

Sister Society Meeting on Global Education Development and Collaboration: Meeting Report.

Chuang LT, Randall TC, Denny L, Johnston CM, Schmeler KM, Covens AL, Cibula D, Bookman MA, Rawal S, DePetrillo D, Nam JH, Goodman A, Naik R, Manchanda R, Gaffney DK, Small W Jr, Creutzberg C, Rattray C, Kesic V, Paraja R, Eiken M, Belleson K, Coleman RL, Barakat RR, Trimble EL, Quinn M.

Int J Gynecol Cancer. 2016 Jul;26(6):1186-8. doi: 10.1097/IGC.0000000000000735.

PMID:
27327155
23.

Optimal primary therapy of ovarian cancer.

Bookman MA.

Ann Oncol. 2016 Apr;27 Suppl 1:i58-i62. doi: 10.1093/annonc/mdw088. Review.

PMID:
27141074
24.

Reply to F.M. Muggia.

Bookman MA, Brady MF.

J Clin Oncol. 2016 Mar 10;34(8):884. doi: 10.1200/JCO.2015.63.4303. Epub 2016 Feb 1. No abstract available.

PMID:
26834059
25.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

26.

Reply to G.D. Aletti et al.

Horowitz N, Miller A, Rungruang B, Richard S, Rodriguez N, Bookman MA, Hamilton C, Krivak T, Maxwell GL.

J Clin Oncol. 2015 Oct 20;33(30):3521-2. doi: 10.1200/JCO.2015.62.5707. Epub 2015 Aug 24. No abstract available.

PMID:
26304879
27.

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.

Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM.

J Clin Oncol. 2015 Sep 10;33(26):2841-7. doi: 10.1200/JCO.2015.61.4776. Epub 2015 Aug 3.

28.

Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.

Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente MP, Burger RA.

Gynecol Oncol. 2015 Oct;139(1):17-22. doi: 10.1016/j.ygyno.2015.07.103. Epub 2015 Jul 26.

29.

Intraperitoneal chemotherapy: long-term outcomes revive a long-running debate.

Bookman MA, Brady MF.

J Clin Oncol. 2015 May 1;33(13):1424-6. doi: 10.1200/JCO.2014.60.2797. Epub 2015 Mar 23. No abstract available.

PMID:
25800752
30.

Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.

von Mehren M, Bookman M, Meropol NJ, Weiner LM, Sherman E, Li J, Knoblauch R, Parekh T, Cohen RB.

Cancer Chemother Pharmacol. 2015 May;75(5):1047-55. doi: 10.1007/s00280-015-2705-z. Epub 2015 Mar 20.

31.

Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.

Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, Hamilton CA, Krivak TC, Maxwell GL.

J Clin Oncol. 2015 Mar 10;33(8):937-43. doi: 10.1200/JCO.2014.56.3106. Epub 2015 Feb 9.

32.

On the road to PARPi-platin.

Bookman MA.

J Natl Cancer Inst. 2014 May 19;106(6):dju119. doi: 10.1093/jnci/dju119. Print 2014 Jun. No abstract available.

PMID:
24842884
33.

Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.

Tewari KS, Java JJ, Gatcliffe TA, Bookman MA, Monk BJ.

Gynecol Oncol. 2014 Jun;133(3):439-45. doi: 10.1016/j.ygyno.2014.03.013. Epub 2014 Mar 20.

34.

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX.

J Clin Oncol. 2014 Apr 20;32(12):1210-7. doi: 10.1200/JCO.2013.53.6524. Epub 2014 Mar 17.

35.

Better therapeutic trials in ovarian cancer.

Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD.

J Natl Cancer Inst. 2014 Apr;106(4):dju029. doi: 10.1093/jnci/dju029. Epub 2014 Mar 13. Review.

36.

The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.

Fader AN, Java J, Krivak TC, Bristow RE, Tergas AI, Bookman MA, Armstrong DK, Tanner EJ, Gershenson DM.

Gynecol Oncol. 2014 Mar;132(3):560-5. doi: 10.1016/j.ygyno.2013.11.016. Epub 2013 Dec 13.

37.

Do we have a new standard in suboptimal debulked disease?

Bookman MA.

Ann Oncol. 2013 Dec;24 Suppl 10:x37-40. doi: 10.1093/annonc/mdt468. Review. Erratum in: Ann Oncol. 2014 Feb;25(2):547.

PMID:
24265402
38.

Molecular wanderings through the DNA damage response and risk for ovarian cancer.

Bookman MA.

J Natl Cancer Inst. 2014 Jan;106(1):djt350. doi: 10.1093/jnci/djt350. Epub 2013 Nov 21. No abstract available.

PMID:
24262438
39.

Heart of lymphoma: primary mediastinal large B-cell lymphoma with endomyocardial involvement.

Rogowitz E, Babiker HM, Krishnadasan R, Jokerst C, Miller TP, Bookman M.

Case Rep Oncol Med. 2013;2013:814291. doi: 10.1155/2013/814291. Epub 2013 Oct 1.

40.

The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.

Denicoff AM, McCaskill-Stevens W, Grubbs SS, Bruinooge SS, Comis RL, Devine P, Dilts DM, Duff ME, Ford JG, Joffe S, Schapira L, Weinfurt KP, Michaels M, Raghavan D, Richmond ES, Zon R, Albrecht TL, Bookman MA, Dowlati A, Enos RA, Fouad MN, Good M, Hicks WJ, Loehrer PJ Sr, Lyss AP, Wolff SN, Wujcik DM, Meropol NJ.

J Oncol Pract. 2013 Nov;9(6):267-76. doi: 10.1200/JOP.2013.001119. Epub 2013 Oct 15.

41.

Survival in women with grade 1 serous ovarian carcinoma.

Fader AN, Java J, Ueda S, Bristow RE, Armstrong DK, Bookman MA, Gershenson DM; Gynecologic Oncology Group (GOG).

Obstet Gynecol. 2013 Aug;122(2 Pt 1):225-32. doi: 10.1097/AOG.0b013e31829ce7ec.

42.

Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Burger RA, Brady MF, Rhee J, Sovak MA, Kong G, Nguyen HP, Bookman MA.

Gynecol Oncol. 2013 Oct;131(1):21-6. doi: 10.1016/j.ygyno.2013.07.100. Epub 2013 Jul 29.

43.

Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182.

Rodriguez N, Miller A, Richard SD, Rungruang B, Hamilton CA, Bookman MA, Maxwell GL, Horowitz NS, Krivak TC.

Gynecol Oncol. 2013 Sep;130(3):487-92. doi: 10.1016/j.ygyno.2013.06.017. Epub 2013 Jun 17.

PMID:
23791702
44.

Should studies of maintenance therapy be maintained in women with ovarian cancer?

Bookman MA.

J Gynecol Oncol. 2013 Apr;24(2):105-7. doi: 10.3802/jgo.2013.24.2.105. Epub 2013 Apr 5. No abstract available.

45.

First-line chemotherapy in epithelial ovarian cancer.

Bookman MA.

Clin Obstet Gynecol. 2012 Mar;55(1):96-113. doi: 10.1097/GRF.0b013e31824b45da. Review.

PMID:
22343232
46.

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.

Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, Krivak TC.

Gynecol Oncol. 2012 May;125(2):421-6. doi: 10.1016/j.ygyno.2012.01.008. Epub 2012 Jan 16.

47.

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group.

N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.

PMID:
22204724
48.

Update of randomized trials in first-line treatment.

Bookman MA.

Ann Oncol. 2011 Dec;22 Suppl 8:viii52-viii60. doi: 10.1093/annonc/mdr466. Review.

PMID:
22180402
49.

Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.

Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H, DeLoia JA.

Gynecol Oncol. 2012 Mar;124(3):575-81. doi: 10.1016/j.ygyno.2011.11.022. Epub 2011 Nov 21.

50.

Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.

Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS.

Gynecol Oncol. 2012 Jan;124(1):53-8. doi: 10.1016/j.ygyno.2011.09.024. Epub 2011 Oct 26.

PMID:
22032836

Supplemental Content

Loading ...
Support Center